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Introduction
Colorectal cancer (CRC) is one of the most commonly diag-
nosed malignant neoplasms worldwide, with an estimated 1.4 mil-
lion occurrences and almost 700,000 deaths in 2012. Regions of 
high incidence are Northern America, Europe, and Australia/New 
Zealand [1]. In contrast to a mainly rising incidence rate over the 
last 20–30 years, specific mortality rates of CRC have decreased in 
a large number of countries, most likely due to screening examina-
tions, prevention programs, and improved treatment options [1]. 
Advances in multimodal treatment strategies involving all major 
oncologic disciplines have contributed to a remarkably improved 
prognosis for affected patients. For rectal cancer in particular, ra-
diotherapy has been established as a mainstay of treatment along-
side surgery. In the present article, we review the role of radiother-
apy in the management of CRC with a special focus on current 
treatment standards for locally advanced rectal cancer and provide 
an outlook on future challenges and approaches. 
Neoadjuvant Radiotherapy
At the end of the 1980s and during the 1990s, evidence was 
growing that an addition of radiotherapy to exclusively surgical 
treatment of rectal cancer could improve patients’ prognosis. After 
the first prospective trials initiated in that phase had released their 
long-term results, a paradigm shift in the management of locally 
advanced rectal cancer took place towards multimodal treatment 
strategies. 
The Swedish Rectal Cancer Trial was one of the first major stud-
ies in which a significant benefit of neoadjuvant irradiation com-
pared to surgery alone [2] was found. By preoperatively applying a 
short-course radiotherapy (SC-RT) of 5 × 5 Gy, the overall survival 
(OS) was significantly improved from 30 to 38% (p = 0.008), and 
the local recurrence rate (LRR) decreased from 26 to 9% (p < 
Keywords
Radiotherapy · Colorectal cancer · Chemoradiotherapy · 
Rectal cancer
Summary
Background: Multimodal treatment approaches are in-
dispensable for patients with advanced-stage colorectal 
cancer. Radiotherapy has been established as essential 
part of perioperative concepts and was introduced as an 
option to face challenges such as local relapse or oligo-
metastases. Methods: A literature review was performed 
to summarize evidence and current standards of radio-
therapeutic concepts in the treatment of colorectal can-
cer. Results: For stage II/III rectal cancer, neoadjuvant 
 radiotherapy is superior to adjuvant treatment. Two pre-
operative regimens have been established and are com-
monly used with different objectives: short-course 
radiotherapy (SC-RT) and long-course chemoradiother-
apy (LC-CRT). Both reduce the risk of local relapse. Ad-
ditionally, LC-CRT aims at downsizing the tumor to po-
tentially reduce radicalness of surgery. There is increas-
ing evidence that not all stage II/III rectal cancer patients 
need neoadjuvant irradiation but also that in some cases 
surgery might be omitted. Stereotactic body radiother-
apy (SBRT) of the liver shows high rates of local control 
in oligometastatic patients. Intraoperative and particle 
radiotherapy extend the spectrum of treatment options 
for locally recurrent patients. Conclusion: Radiothera-
peutic concepts are crucial for the primary management 
of locally advanced colorectal cancer and can essentially 
contribute to treatment approaches in locally recurrent, 
oligometastatic or palliative patients.
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0.001). However, as surgical quality was also improved dramati-
cally by the introduction of total mesorectal excision (TME) result-
ing in significantly lower recurrence rates [3, 4], the Swedish data 
from the pre-TME era are not applicable to the present. In a Dutch 
trial, the addition of preoperative SC-RT to TME surgery improved 
LRR from 11 to 5% (p < 0.0001) but did not result in a better OS 
(49 vs. 48%; p = 0.86) [5]. In the MRC CR07 trial, preoperative 
SC-RT was tested against selective adjuvant chemoradiation for 
high-risk patients with a positive circumferential resection margin 
(CRM+). TME was not obligatory but equably balanced between 
both treatment arms. Though selective postoperative treatment did 
not influence OS after 3 years (76.7 vs. 74.4%; p = 0.04), LRR was 
remarkably higher with 10.6% compared to preoperative SC-RT 
with 4.4% (p < 0.0001) [6]. 
Alternatively to SC-RT, the combination of normofractionated 
irradiation with radiation doses between 45 and 50.4 Gy and si-
multaneous application of chemotherapy was established as long-
course chemoradiotherapy (LC-CRT). The German CAO/ARO/
AIO-94 trial introduced a 5-fluorouracil(5-FU)-based CRT ap-
proach and demonstrated an advantage of preoperative over post-
operative application in terms of 10-year LRR (7.1 vs. 10.1%; p = 
0.048) but not in OS [7, 8]. Omitting the chemotherapeutic com-
ponent in preoperative long-course treatment does not affect OS 
negatively but results in a worse LRR as Gérard et al. [9] were able 
to demonstrate. Alternatively to 5-FU-based approaches, capecit-
abine can be used in preoperative LC-CRT [10]. 
With two available neoadjuvant concepts, SC-RT and LC-CRT, 
the question arose whether one of them is superior to the other and 
should thus be used preferably in daily practice. Several works ad-
dressed this topic, and Bujko et al. [11] presented first results in a 
randomized controlled trial. After a median follow-up of 4 years, 
no differences in OS or LRR were observed. The Trans-Tasman 
Radiation Oncology Group presented comparable prognostic re-
sults in 2012 for both strategies, with a 5-year OS of 74 versus 70% 
(p = 0.62) and a 3-year LRR of 7.5 versus 4.4% (p = 0.24) for SC-RT 
versus LC-CRT [12]. However, both studies were criticized because 
of a rather small patient number and short follow-up. Further, two 
Cochrane Database reviews with the same question and quite simi-
lar inclusion criteria (stage III or stage II/III) tried to determine the 
preferable concept, and both found a superiority of LC-CRT com-
pared to radiotherapy alone in terms of LRR [13, 14]. However, the 
meta-analyses contained only 5 or 6 studies with very heterogene-
ous treatment regimens and in part cohorts with pre-TME surgery 
limiting the informative value.
From a clinical point of view, SC-RT and LC-CRT are not com-
peting but complementary strategies with a separate scope of use 
and partly different therapeutic goals: concordantly, both strategies 
aim to reduce the risk of local relapse. But as reflected in the major 
clinical guidelines [15–17], SC-RT is commonly recommended in 
early T3 stage without lymph node involvement, whereas LC-CRT 
is indicated for advanced T3 and T4 tumors with positive clinical 
circumferential resection margin (cCRM+) and/or positive lymph 
nodes to additionally downsize the tumor. The downsize effect 
aims at increasing the probability of R0 resection and in special 
cases to preserve the sphincter muscle. Adjuvant chemoradiation 
should be avoided by thorough diagnostic work-up before treat-
ment onset. Further, the management of proximal rectal cancer, 
i.e. 12–16 cm from the anal verge, is debated controversially due to 
the anatomical setting und the underrepresentation in the men-
tioned studies. A detailed overview of the relevant, major rand-
omized trials for neoadjuvant SC-RT or LC-CRT is shown in 
table 1.
Toxicity
Besides the undisputed importance of acute toxicity in the eval-
uation of a treatment modality, late side effects of neoadjuvant ra-
diotherapy in rectal cancer deserve special attention due to the 
functional sensitivity of concerned structures like the anal sphinc-
ter or the urinary tract. Long-term follow-up data from the Dutch 
trial [18] or Swedish cohorts [19] suggested high rates of fecal and 
urinary incontinence after SC-RT compared to surgery alone, thus 
impairing quality of life. However, from today’s perspective, old ra-
diation techniques were used in these trials. More recent toxicity 
data from the British MRC CR07 trial also showed increased fecal 
incontinence rates associated with SC-RT; however, in most of the 
affected patients changes were reported on a low-grade level with 
rather minor impact on the quality of life [20]. 
Higher rates of acute toxicity are rather observed with LC-CRT 
than SC-RT, but incidence rates of late side effects do not show sig-
nificant differences [11–14]. Gender-specific analyses of toxicity 
showed a significantly higher rate of hematologic and acute organ 
toxicity for female patients in the cohort of the German CAO/ARO/
AIO-94 trial [21] and an increased rate of dyspareunia and vaginal 
dryness [22]. However, these data also resulted from outdated treat-
ment application modes. Further, there was a slightly increased rate 
of sexual dysfunction compared to surgery alone in male patients 
treated with SC-RT; however, the main reason for sexual dysfunc-
tion was surgical morbidity[0] [20]. [20]. A recent pooled analysis 
of the Dutch trial [5] and the PORTEC trials for RT of endometrial 
cancer [23, 24] did not show an increased rate of secondary malig-
nancies associated with RT [25]. However, there is no comparable 
analysis for combined CRT. Finally, neoadjuvant RT or CRT do not 
seem to deteriorate perioperative morbidity [26, 27].
Future Perspectives
Technical progress due to advanced radiation delivery tech-
niques has found its way into the treatment of rectal cancer as well. 
Especially intensity-modulated radiotherapy (IMRT) has been 
broadly established in clinical use and has shown potential benefits 
with decreased toxicity for rectal cancer patients by reducing the 
radiation dose applied to the organs at risk [28, 29]. With particle 
irradiation (e.g. protons) even higher conformity of the therapeutic 
dose level and lower doses at healthy tissue seem possible, and the 
first planning studies have shown encouraging results [30]. On the 
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one hand, this development is expected to reduce rather high toxic-
ity rates reported in the large, major trials mentioned above. On 
the other hand, a higher precision of the radiation beam also bears 
a higher risk of geographical miss of the target volume. Hence, ad-
vanced delivery techniques, especially particle RT, need further 
clinical validation.
Besides these technical aspects of dose delivery, the main future 
challenge for the management of rectal cancer is the identification 
of certain risk constellations that allow more differentiated and 
personalized treatment recommendations, especially for the highly 
debated heterogeneous group of stage II/III patients. Currently, 
two major approaches can be observed and are described in the 
following.
Local De-Escalation
After neoadjuvant RT has become a general recommendation 
for all stage II/III rectal cancer patients, the question emerged 
whether actually every patient of this group needs preoperative 
treatment, and, if not, how patients who probably will not benefit 
can be selected [31, 32]. Indeed, the introduction of TME lead to a 
significant improvement of local tumor control, and the OS advan-
tage of neoadjuvant RT vanished. However, the addition of neoad-
juvant RT to TME surgery reduces the risk of local relapse approxi-
mately by 50%, e.g. from 11 to 5% in the Dutch trial [5]. Estimated 
from that data, the number needed to treat in order to prevent one 
local relapse is approximately 20. The basic hypothesis for the 
identification of patients suitable for an exclusively surgical con-
cept is that patients with negative nodal status, negative cCRM, and 
safe distance to the anal verge are unlikely to benefit from RT. So 
far, retrospective data suggest the permissibility of that approach, 
but at the same time they are too biased in terms of imbalanced 
collectives, short follow-up, and uncontrolled data to conclusively 
contribute to the question [26]. Further, very sensitive and specific 
diagnostic tools are necessary to prospectively select these patients. 
With an advanced thin slice protocol of magnetic resonance imag-
ing (MRI), the MERCURY study group has developed a strong tool 
with a high prediction rate of pathological CRM status and a low 
rate of false-negative findings [33, 34]. However, the relevance of 
nodal status remains unclear. Further, there are findings from 
major studies that conflict with the hypothesis mentioned above 
and are not entirely understood until today. Whereas the entire co-
hort of the Dutch trial showed a better LRR with SC-RT without 
differences in OS, an OS benefit of 50 or 40% was found only in the 
subgroup of patients with negative CRM when SC-RT was applied 
or not [5]. The authors of the British MRC CR07 trial presented 
similar results [6] and additionally demonstrated that even patients 
with optimal TME significantly benefit from SC-RT in terms of 
LRR (1 vs. 7%) [35]. There are hints that a subgroup of patients 
does not require preoperative SC-RT or LC-CRT, but from today’s 
perspective reliable criteria to identify these patients are lacking.
The opposite question to that of local de-escalation is whether 
all patients undergoing neoadjuvant RT actually need surgery. For 
patients after LC-CRT, pathological complete remission (pCR) 
rates of 8–20% are reported [7, 11, 12, 36, 37]. These very good re-
Table 1. Key trials for neoadjuvant RT of rectal cancer
Reference Treatment n TME FU OS LRR pCR Comment
Folkesson et al. [2] i) SC-RT + surg 908 no 156 13 years: 38%a 13 years: 9%a n.d.
Swedish Rectal Cancer Trial ii) surg       13 years: 30%a 13 years: 26%a n.d.  
van Gijn et al. [5] i) SC-RT + surg 1,861 yes 139 10 years: 49% 10 years: 5%a n.d.
Dutch Rectal Cancer Trial ii) surg       10 years: 48% 10 years: 11%a n.d.  
Sebag-Montefiore et al. [6] i) SC-RT + surg 1,350 (yes)  48 3 years: 51.5% 3 years: 4.4%a n.d. TME optional
MRC CR07 ii) surg + LC-CRT 
(CRM+)
    3 years: 53.4% 3 years: 10.6%a n.d. balanced
Gérard et al. [9] i) LC-CRT + surg 733 (yes)  81 5 years: 67.4% 5 years: 8.1%a 11.4%a TME recommended
FFCD 9203 ii) LC-RT + surg       5 years: 67.9% 5 years: 16.5%a 3.6%a  
Sauer et al. [8] i) LC-CRT + surg 799 yes 134 10 years: 59.6% 10 years: 7.1%a 8%
CAO/ARO/AIO-94 ii) surg + LC-CRT       10 years: 59.9% 10 years: 10.1%a n.a.  
Bujko et al. [11] i) SC-RT + surg 312 yes  48 4 years: 67.2% 4 years: 10.6% 0.7%a
ii) LC-CRT + surg       4 years: 66.2% 4 years: 15.6% 16.1%a  
Ngan et al. [12] i) SC-RT + surg 326 (no)  71 5 years: 74% 3 years: 7.5% 1%a TME not routinely
TROG 01.04 ii) LC-CRT + surg       5 years: 70% 3 years: 4.4% 15%a (NHMRC GL 1999)
aStatistically significant.
n = Patient number; TME = total mesorectal excision; FU = median follow-up; OS = overall survival; LRR = local relapse rate; pCR = pathological complete remis-
sion; SC-RT = short-course radiotherapy; surg = surgery; LC-CRT = long-course chemoradiotherapy (5-FU- or capecitabine-based); CRM+ = positive circumfer-
ential resection margin; n.d. = not done.
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sponders might be eligible for a non-surgical approach. The first 
experiences with a wait-and-see policy instead of surgery in a 
smaller number of patients with clinical complete remission (cCR) 
showed encouraging results [38, 39]. Further, radiation and/or 
chemotherapeutic dose intensification beyond the usual LC-CRT 
regimen potentially increases the rate of cCR [40, 41]. Though sal-
vage strategies seem basically feasible, a rather high 1-year LRR of 
15–35% [40, 42] compared to the standard surgery-based approach 
is to be considered critically. Furthermore, the questions of optimal 
patient selection, adequate response assessment, and appropriate 
follow-up remain unanswered. So far, due to a lack of randomized 
evidence, organ-preserving treatment of rectal cancer is not recom-
mended outside of clinical trials [43].
Systemic Escalation
The main debate in rectal cancer management predominantly 
dealt with local treatment strategies for a long time, but nowadays 
local control is excellent thanks to preoperative RT and TME. In 
contrast, overall survival rates are in need of improvement, and the 
major factor limiting the outcome is the appearance of metachro-
nous distant metastases. The main approach to overcome this issue 
is the escalation of systemic therapy in the neoadjuvant setting, e.g. 
by addition of oxaliplatin to 5-FU- or capecitabine-based LC-RCT. 
Rödel et al. [41] demonstrated a significant improvement of the 
pCR rate (17 vs. 13%) and the 3-year disease-free survival rate (75.9 
vs. 71.2%) with versus without oxaliplatin, in the absence of sub-
stantial increases in side effects; however, there was no improve-
ment in OS. The standard use of oxaliplatin remains controversial 
though, especially when considering non-beneficial results from 
other trials with increased toxicity rates [36, 44]. For the subgroup 
of KRAS-wildtype patients, Dewdney et al. [45] have shown a ben-
efit in OS by adding cetuximab to neoadjuvant treatment in a small 
cohort, but the primary objective of the study, i.e. a superior pCR 
rate, was missed. A short overview of remarkable trials with sys-
temic escalation is given in table 2.
Future approaches include further treatment escalation, e.g. 
with induction chemotherapy prior to LC-CRT as examined in the 
currently recruiting German CAO/ARO/AIO-12 trial, as well as 
the identification of favorable subgroups by means of molecular 
parameters potentially offering new treatment targets.
Special Situations
Oligometastases
About 20 years ago, the definition of oligometastatic disease as 
an intermediate cancer stage between locally limited tumor spread 
and disseminated metastases was proposed by Hellman and Weich-
selbaum [46] and has increasingly been established in clinical prac-
tice ever since. The relevance of this concept including local treat-
ment of an assumed systemic disease was demonstrated by some 
comprehensive works investigating the role of surgery for CRC liver 
metastases and showing 5-year OS rates of 25–47% [47–50]. Alter-
natively, less invasive locally ablative concepts such as radiofre-
quency ablation (RFA) or stereotactic body radiotherapy (SBRT) 
have emerged. Though large comparative trials are lacking, SBRT 
for liver metastases has shown beneficial results in CRC patients 
with 1-year local control rates of 56–100% [51]. Thus, SBRT is an 
excellent option for the local treatment of metastases with a good 
outcome and low toxicity rates, particularly for patients not suitable 
for surgery due to comorbidities or difficult technical resectability.
Re-Irradiation
In case of relapse, R0 resection is the most important prognostic 
marker. Hence, the use of surgery as radically as possible and 
Table 2. Key trials for systemic escalation in neoadjuvant RT of rectal cancer
Reference Treatment n TME FU OS LRR pCR, % Comment
Aschele et al. [44] LC-CRT (+ ox) + surg vs. 747 yes n.a. n.a. n.a. 16 response analysis
STAR-01 LC-CRT + surg n.a. n.a. n.a. 16 survival not published yet
Gérard et al. [36] LC-CRT (+ ox) + surg vs. 598 yes 37 3 years: 87.6% 3 years: 4.4% 19.2
ACCORD 12/0405  
PRODIGE 2 
LC-CRT + surg 3 years: 88.3% 3 years: 6.1% 13.9
Rödel et al. [41] LC-CRT (+ ox) + surg 1,236 yes 50 3 years: 88.7% 3 years: 2.9% 17a
CAO/ARO/AIO-04 LC-CRT + surg 3 years: 88.0% 3 years:4.6% 13a
Dewdney et al. [45] CHT + LC-CRT (+ ox + cet) + surg 90 yes 37 2 years: 91.3%a 3 years: 2.2% 11
EXPERT-C CHT + LC-CRT (+ ox) + surg 32 2 years: 81.8%a 3 years: 4.5%  9
aStatistically significant.
n = Patient number; TME = total mesorectal excision; FU = median follow-up; OS = overall survival; LRR = local relapse rate; pCR = pathological complete  
remission; ox = oxaliplatin; surg = surgery; cet = cetuximab; LC-CRT = long-course chemoradiotherapy (5-FU- or capecitabine-based); CHT = chemotherapy;  
n.a. = not applicable.
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maintainable is the standard of care for locally recurrent rectal can-
cer. When safe resection with negative resection margins is ques-
tionable, a combination with neoadjuvant CRT is recommended in 
all patients that have not been treated with SC-RT or LC-CRT in 
first-line therapy. Nevertheless, also in patients with previous pel-
vic RT retreatment is useful under certain limitations. Recent anal-
yses have demonstrated that re-irradiation positively influences 
resectability, resulting in a favorable OS [52]. On average, 30–40 
Gy are applied in repeated RT depending on initial doses and 
elapsed time from initial treatment [53]. However, there is a huge 
variety of applied re-irradiation concepts including normofrac-
tionated external beam RT [54], hyperfractionated regimens [55], 
and intraoperative RT [56–59]. In patients re-irradiated within cu-
rative concepts, median OS is 39–60 months [53]. In patients in 
palliative settings, median OS is 12–16 months, and symptomatic 
relief, i.e. reduction of pain or tumor bleeding, can be achieved in 
the majority of cases [53, 54]. Acute toxicity seems acceptable with 
9–20% (diarrhea), but the assessment of late side effects is difficult 
due to a lack of data so far [53]. Finally, particle RT with protons or 
heavy ions might allow further dose escalation in re-irradiation of 
rectal cancer without increasing toxicity, but clinical results in a 
larger number of patients are lacking [60, 61]. 
Conclusion
Radiotherapeutic concepts are crucial for the primary manage-
ment of locally advanced rectal cancer and a helpful tool in the 
management of recurrent or oligometastatic CRC. Future research 
will have to focus on a better treatment selection for stage II/III 
patients in the primary setting and to find strategies to prevent 
prospective failure and improve long-term OS.
Disclosure Statement
The authors declare that they have no financial support or conflicts of inter-
est pertaining to this report.
References
 1 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, 
Jemal A: Global cancer statistics, 2012. CA Cancer J 
Clin 2015; 65: 87–108.
 2 Folkesson J, Birgisson H, Pahlman L, Cedermark B, 
Glimelius B, Gunnarsson U: Swedish Rectal Cancer 
Trial: long lasting benefits from radiotherapy on sur-
vival and local recurrence rate. J Clin Oncol 2005; 23: 
5644–5650.
 3 Heald RJ, Husband EM, Ryall RD: The mesorectum in 
rectal cancer surgery – the clue to pelvic recurrence? Br 
J Surg 1982; 69: 613–616.
 4 Heald RJ, Karanjia ND: Results of radical surgery for 
rectal cancer. World J Surg 1992; 16: 848–857.
 5 van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg 
EM, Putter H, Wiggers T, Rutten HJ, Pahlman L, 
Glimelius B, van de Velde CJ; Dutch Colorectal Cancer 
Group: Preoperative radiotherapy combined with total 
mesorectal excision for resectable rectal cancer: 12-year 
follow-up of the multicentre, randomised controlled 
TME trial. Lancet Oncol 2011; 12: 575–582.
 6 Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, 
Grieve R, Khanna S, Quirke P, Couture J, de Metz C, 
Myint AS, Bessell E, Griffiths G, Thompson LC, Par-
mar M: Preoperative radiotherapy versus selective 
postoperative chemoradiotherapy in patients with rec-
tal cancer (MRC CR07 and NCIC-CTG C016): a mul-
ticentre, randomised trial. Lancet 2009; 373: 811–820.
 7 Sauer R, Becker H, Hohenberger W, Rodel C, Witte-
kind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, 
Hess CF, Karstens JH, Liersch T, Schmidberger H, 
Raab R; German Rectal Cancer Study Group: Preoper-
ative versus postoperative chemoradiotherapy for rec-
tal cancer. N Engl J Med 2004; 351: 1731–1740.
 8 Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger 
W, Hess C, Becker H, Raab HR, Villanueva MT, Witz-
igmann H, Wittekind C, Beissbarth T, Rodel C: Preop-
erative versus postoperative chemoradiotherapy for 
locally advanced rectal cancer: results of the German 
CAO/ARO/AIO-94 randomized phase III trial after a 
median follow-up of 11 years. J Clin Oncol 2012; 30: 
1926–1933.
 9 Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet 
O, Closon-Dejardin MT, Untereiner M, Leduc B, 
Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz 
R, Ducreux M, Bedenne L: Preoperative radiotherapy 
with or without concurrent fluorouracil and leucov-
orin in T3–4 rectal cancers: results of FFCD 9203. J 
Clin Oncol 2006; 24: 4620–4625.
10 Hofheinz RD, Wenz F, Post S, et al: Chemoradiother-
apy with capecitabine versus fluorouracil for locally 
advanced rectal cancer: a randomised, multicentre, 
non-inferiority, phase 3 trial. Lancet Oncol 2012; 13: 
579–588.
11 Bujko K, Nowacki MP, Nasierowska-Guttmejer A, 
Michalski W, Bebenek M, Kryj M: Long-term results 
of a randomized trial comparing preoperative short-
course radiotherapy with preoperative conventionally 
fractionated chemoradiation for rectal cancer. Br J 
Surg 2006; 93: 1215–1223.
12 Ngan SY, Burmeister B, Fisher RJ, Solomon M, Gold-
stein D, Joseph D, Ackland SP, Schache D, McClure B, 
McLachlan SA, McKendrick J, Leong T, Hartopeanu 
C, Zalcberg J, Mackay J: Randomized trial of short-
course radiotherapy versus long-course chemoradia-
tion comparing rates of local recurrence in patients 
with T3 rectal cancer: Trans-Tasman Radiation Oncol-
ogy Group trial 01.04. J Clin Oncol 2012; 30: 3827–
3833.
13 De Caluwe L, Van Nieuwenhove Y, Ceelen WP: Preop-
erative chemoradiation versus radiation alone for stage 
II and III resectable rectal cancer. Cochrane Database 
Syst Rev 2013; 2:CD006041.
14 McCarthy K, Pearson K, Fulton R, Hewitt J: Pre-opera-
tive chemoradiation for non-metastatic locally ad-
vanced rectal cancer. Cochrane Database Syst Rev 2012; 
12:CD008368.
15 National Comprehensive Cancer Network (NCCN), 
NCCN Clinical Practical Guidelines in Oncology: Rec-
tal Cancer; version 01.2016. www.nccn.org/professionals/ 
physician_gls/pdf/rectal.pdf (last accessed January 24, 
2016).
16 Glimelius B, Tiret E, Cervantes A, Arnold D; ESMO 
Guidelines Working Group: Rectal cancer: ESMO 
Clinical Practice Guidelines for diagnosis, treatment 
and follow-up. Ann Oncol 2013; 24(suppl 6):vi81–88.
17 Leitlinienprogramm Onkologie (Deutsche Krebsge-
sellschaft Deutsche Krebshilfe, AWMF), S3-Leitlinie 
Kolorektales Karzinom, Langversion 1.1, 2014, AWMF 
Registrierungsnummer: 021–007OL. www.leitlinien-
programm-onkologie.de/Leitlinien.7.0.html (last accessed 
January 24, 2016).
18 Peeters KC, van de Velde CJ, Leer JW, Martijn H, Jun-
ggeburt JM, Kranenbarg EK, Steup WH, Wiggers T, 
Rutten HJ, Marijnen CA: Late side effects of short-
course preoperative radiotherapy combined with total 
mesorectal excision for rectal cancer: increased bowel 
dysfunction in irradiated patients – a Dutch colorectal 
cancer group study. J Clin Oncol 2005; 23: 6199–6206.
19 Pollack J, Holm T, Cedermark B, Altman D, Holm-
strom B, Glimelius B, Mellgren A: Late adverse effects 
of short-course preoperative radiotherapy in rectal 
cancer. Br J Surg 2006; 93: 1519–1525.
20 Stephens RJ, Thompson LC, Quirke P, Steele R, Grieve 
R, Couture J, Griffiths GO, Sebag-Montefiore D: Im-
pact of short-course preoperative radiotherapy for rec-
tal cancer on patients’ quality of life: data from the 
Medical Research Council CR07/National Cancer In-
stitute of Canada Clinical Trials Group C016 rand-
omized clinical trial. J Clin Oncol 2010; 28: 4233–4239.
21 Wolff HA, Conradi LC, Beissbarth T, Leha A, Hohen-
berger W, Merkel S, Fietkau R, Raab HR, Tschmelitsch 
J, Hess CF, Becker H, Wittekind C, Sauer R, Rodel C, 
Liersch T; German Rectal Cancer Study Group: Gen-
der affects acute organ toxicity during radiochemo-
therapy for rectal cancer: long-term results of the Ger-
man CAO/ARO/AIO-94 phase III trial. Radiother 
Oncol 2013; 108: 48–54.
22 Bruheim K, Tveit KM, Skovlund E, Balteskard L, 
Carlsen E, Fossa SD, Guren MG: Sexual function in fe-
males after radiotherapy for rectal cancer. Acta Oncol 
2010; 49: 826–832.
Radiotherapy for Colorectal Cancer Visc Med 2016;32:172–177 177
23 Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, 
Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, 
Mens JW, Slot A, Kroese MC, van Bunningen BN, An-
sink AC, van Putten WL, Creutzberg CL; PORTEC 
Study Group: Vaginal brachytherapy versus pelvic ex-
ternal beam radiotherapy for patients with endome-
trial cancer of high-intermediate risk (PORTEC-2): an 
open-label, non-inferiority, randomised trial. Lancet 
2010; 375: 816–823.
24 Nout RA, van de Poll-Franse LV, Lybeert ML, War-
lam-Rodenhuis CC, Jobsen JJ, Mens JW, Lutgens LC, 
Pras B, van Putten WL, Creutzberg CL: Long-term 
outcome and quality of life of patients with endome-
trial carcinoma treated with or without pelvic radio-
therapy in the post operative radiation therapy in en-
dometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol 
2011; 29: 1692–1700.
25 Wiltink LM, Nout RA, Fiocco M, Meershoek-Klein 
Kranenbarg E, Jurgenliemk-Schulz IM, Jobsen JJ, 
Nagtegaal ID, Rutten HJ, van de Velde CJ, Creutzberg 
CL, Marijnen CA: No increased risk of second cancer 
after radiotherapy in patients treated for rectal or en-
dometrial cancer in the randomized TME, PORTEC-1, 
and PORTEC-2 trials. J Clin Oncol 2015; 33: 1640–1646.
26 Kulu Y, Tarantino I, Billeter AT, Diener MK, Schmidt 
T, Buchler MW, Ulrich A: Comparative outcomes of 
neoadjuvant treatment prior to total mesorectal exci-
sion and total mesorectal excision alone in selected 
stage II/III low and mid rectal cancer. Ann Surg Oncol 
2016; 23: 106–113.
27 Ulrich A, Weitz J, Slodczyk M, Koch M, Jaeger D, 
Munter M, Buchler MW: Neoadjuvant treatment does 
not influence perioperative outcome in rectal cancer 
surgery. Int J Radiat Oncol Biol Phys 2009; 75: 129–136.
28 Droge LH, Weber HE, Guhlich M, Leu M, Conradi LC, 
Gaedcke J, Hennies S, Herrmann MK, Rave-Frank M, 
Wolff HA: Reduced toxicity in the treatment of locally 
advanced rectal cancer: a comparison of volumetric 
modulated arc therapy and 3D conformal radiotherapy. 
BMC Cancer 2015; 15: 750.
29 Samuelian JM, Callister MD, Ashman JB, Young-
Fadok TM, Borad MJ, Gunderson LL: Reduced acute 
bowel toxicity in patients treated with intensity-modu-
lated radiotherapy for rectal cancer. Int J Radiat Oncol 
Biol Phys 2012; 82: 1981–1987.
30 Wolff HA, Wagner DM, Conradi LC, Hennies S, 
Ghadimi M, Hess CF, Christiansen H: Irradiation with 
protons for the individualized treatment of patients 
with locally advanced rectal cancer: a planning study 
with clinical implications. Radiother Oncol 2012; 102: 
30–37.
31 Lai LL, Fuller CD, Kachnic LA, Thomas CR Jr: Can 
pelvic radiotherapy be omitted in select patients with 
rectal cancer? Semin Oncol 2006; 33(6 suppl 11):S70–
74.
32 Ulrich A, Weitz J, Buchler MW: Rectal cancer. How 
much radiotherapy do surgery patients need? (Article 
in German). Chirurg 2009; 80: 266–273.
33 Battersby NJ, How P, Moran B, Stelzner S, West NP, 
Branagan G, Strassburg J, Quirke P, Tekkis P, Pedersen 
BG, Gudgeon M, Heald B, Brown G, Group MIS: Pro-
spective validation of a low rectal cancer magnetic res-
onance imaging staging system and development of a 
local recurrence risk stratification model: the MER-
CURY II study. Ann Surg 2015; 263: 751–760.
34 MERCURY Study Group: Extramural depth of tumor 
invasion at thin-section MR in patients with rectal can-
cer: results of the MERCURY study. Radiology 2007; 
243: 132–139.
35 Quirke P, Steele R, Monson J, Grieve R, Khanna S, 
Couture J, O’Callaghan C, Myint AS, Bessell E, 
Thompson LC, Parmar M, Stephens RJ, Sebag-Monte-
fiore D; MRC CR07/NCIC-CTG CO16 Trial Investiga-
tors; NCRI Colorectal Cancer Study Group: Effect of 
the plane of surgery achieved on local recurrence in 
patients with operable rectal cancer: a prospective 
study using data from the MRC CR07 and NCIC-CTG 
CO16 randomised clinical trial. Lancet 2009; 373: 821–
828.
36 Gerard JP, Azria D, Gourgou-Bourgade S, et al: Clini-
cal outcome of the ACCORD 12/0405 PRODIGE 2 
randomized trial in rectal cancer. J Clin Oncol 2012; 30: 
4558–4565.
37 Rodel C, Liersch T, Becker H, et al; German Rectal 
Cancer Study Group: Preoperative chemoradiotherapy 
and postoperative chemotherapy with fluorouracil and 
oxaliplatin versus fluorouracil alone in locally ad-
vanced rectal cancer: initial results of the German 
CAO/ARO/AIO-04 randomised phase 3 trial. Lancet 
Oncol 2012; 13: 679–687.
38 Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, 
Ribeiro U Jr, Silva e Sousa AH J., Campos FG, Kiss DR, 
Gama-Rodrigues J: Operative versus nonoperative 
treatment for stage 0 distal rectal cancer following 
chemoradiation therapy: long-term results. Ann Surg 
2004; 240: 711–717; discussion 717–718.
39 Maas M, Beets-Tan RG, Lambregts DM, Lammering 
G, Nelemans PJ, Engelen SM, van Dam RM, Jansen 
RL, Sosef M, Leijtens JW, Hulsewe KW, Buijsen J, 
Beets GL: Wait-and-see policy for clinical complete re-
sponders after chemoradiation for rectal cancer. J Clin 
Oncol 2011; 29: 4633–4640.
40 Appelt AL, Ploen J, Harling H, Jensen FS, Jensen LH, 
Jorgensen JC, Lindebjerg J, Rafaelsen SR, Jakobsen A: 
High-dose chemoradiotherapy and watchful waiting 
for distal rectal cancer: a prospective observational 
study. Lancet Oncol 2015; 16: 919–927.
41 Rodel C, Graeven U, Fietkau R, et al; German Rectal 
Cancer Study Group: Oxaliplatin added to fluoroura-
cil-based preoperative chemoradiotherapy and postop-
erative chemotherapy of locally advanced rectal cancer 
(the German CAO/ARO/AIO-04 study): final results 
of the multicentre, open-label, randomised, phase 3 
trial. Lancet Oncol 2015; 16: 979–989.
42 Habr-Gama A, Gama-Rodrigues J, Sao Juliao GP, Pro-
scurshim I, Sabbagh C, Lynn PB, Perez RO: Local re-
currence after complete clinical response and watch 
and wait in rectal cancer after neoadjuvant chemora-
diation: impact of salvage therapy on local disease con-
trol. Int J Radiat Oncol Biol Phys 2014; 88: 822–828.
43 Marijnen CA: Organ preservation in rectal cancer: 
have all questions been answered? Lancet Oncol 2015; 
16:e13–22.
44 Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Ro-
sati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti 
P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Sil-
vano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo 
M, Boni L: Primary tumor response to preoperative 
chemoradiation with or without oxaliplatin in locally 
advanced rectal cancer: pathologic results of the 
STAR-01 randomized phase III trial. J Clin Oncol 
2011; 29: 2773–2780.
45 Dewdney A, Cunningham D, Tabernero J, Capdevila J, 
Glimelius B, Cervantes A, Tait D, Brown G, Wother-
spoon A, Gonzalez de Castro D, Chua YJ, Wong R, 
Barbachano Y, Oates J, Chau I: Multicenter rand-
omized phase II clinical trial comparing neoadjuvant 
oxaliplatin, capecitabine, and preoperative radiother-
apy with or without cetuximab followed by total meso-
rectal excision in patients with high-risk rectal cancer 
(EXPERT-C). J Clin Oncol 2012; 30: 1620–1627.
46 Hellman S, Weichselbaum RR: Oligometastases. J Clin 
Oncol 1995; 13: 8–10.
47 House MG, Ito H, Gonen M, Fong Y, Allen PJ, DeMat-
teo RP, Brennan MF, Blumgart LH, Jarnagin WR, 
D’Angelica MI: Survival after hepatic resection for 
metastatic colorectal cancer: trends in outcomes for 
1,600 patients during two decades at a single institu-
tion. J Am Coll Surg 2010; 210: 744–752, 752–754.
48 Nordlinger B, Guiguet M, Vaillant JC, Balladur P, 
Boudjema K, Bachellier P, Jaeck D: Surgical resection 
of colorectal carcinoma metastases to the liver. A prog-
nostic scoring system to improve case selection, based 
on 1568 patients. Association Francaise de Chirurgie. 
Cancer 1996; 77: 1254–1262.
49 Robertson DJ, Stukel TA, Gottlieb DJ, Sutherland JM, 
Fisher ES: Survival after hepatic resection of colorectal 
cancer metastases: a national experience. Cancer 2009; 
115: 752–759.
50 Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gall-
inger S: Survival after hepatic resection for colorectal 
metastases: a 10-year experience. Ann Surg Oncol 2006; 
13: 668–676.
51 Sterzing F, Brunner TB, Ernst I, Baus WW, Greve B, 
Herfarth K, Guckenberger M: Stereotactic body radio-
therapy for liver tumors: principles and practical 
guidelines of the DEGRO Working Group on Stereo-
tactic Radiotherapy. Strahlenther Onkol 2014; 190: 
872–881.
52 van der Meij W, Rombouts AJ, Rutten H, Bremers AJ, 
de Wilt JH: Treatment of locally recurrent rectal carci-
noma in previously (chemo)irradiated patients: a re-
view. Dis Colon Rectum 2016; 59: 148–156.
53 Guren MG, Undseth C, Rekstad BL, Braendengen M, 
Dueland S, Spindler KL, Glynne-Jones R, Tveit KM: 
Reirradiation of locally recurrent rectal cancer: a sys-
tematic review. Radiother Oncol 2014; 113: 151–157.
54 Mohiuddin M, Marks G, Marks J: Long-term results of 
reirradiation for patients with recurrent rectal carci-
noma. Cancer 2002; 95: 1144–1150.
55 Valentini V, Morganti AG, Gambacorta MA, Mohiud-
din M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di 
Russo A, Valvo F, Bolzicco G, Dalla Palma M; Study 
Group for Therapies of Rectal Malignancies (STORM): 
Preoperative hyperfractionated chemoradiation for lo-
cally recurrent rectal cancer in patients previously ir-
radiated to the pelvis: a multicentric phase II study. Int 
J Radiat Oncol Biol Phys 2006; 64: 1129–1139.
56 Haddock MG, Gunderson LL, Nelson H, Cha SS, 
Devine RM, Dozois RR, Wolff BG: Intraoperative irra-
diation for locally recurrent colorectal cancer in previ-
ously irradiated patients. Int J Radiat Oncol Biol Phys 
2001; 49: 1267–1274.
57 Haddock MG, Miller RC, Nelson H, Pemberton JH, 
Dozois EJ, Alberts SR, Gunderson LL: Combined mo-
dality therapy including intraoperative electron irradi-
ation for locally recurrent colorectal cancer. Int J Radiat 
Oncol Biol Phys 2011; 79: 143–150.
58 Roeder F, Goetz JM, Habl G, Bischof M, Krempien R, 
Buechler MW, Hensley FW, Huber PE, Weitz J, Debus 
J: Intraoperative electron radiation therapy (IOERT) in 
the management of locally recurrent rectal cancer. 
BMC Cancer 2012; 12: 592.
59 Rutten HJ, Mannaerts GH, Martijn H, Wiggers T: In-
traoperative radiotherapy for locally recurrent rectal 
cancer in The Netherlands. Eur J Surg Oncol 2000; 
(26 suppl A):S16–20.
60 Combs SE, Kieser M, Habermehl D, Weitz J, Jager D, 
Fossati P, Orrechia R, Engenhart-Cabillic R, Potter R, 
Dosanjh M, Jakel O, Buchler MW, Debus J: Phase I/II 
trial evaluating carbon ion radiotherapy for the treat-
ment of recurrent rectal cancer: the PANDORA-01 
trial. BMC Cancer 2012; 12: 137.
61 Habermehl D, Wagner M, Ellerbrock M, Buchler MW, 
Jakel O, Debus J, Combs SE: Reirradiation using carbon 
ions in patients with locally recurrent rectal cancer at 
HIT: first results. Ann Surg Oncol 2015; 22: 2068–2074.
